Method of preparing monoclinic ruthenium oxide

A hydrothermal reaction using specific solvents and gases with tetragonal ruthenium oxide yields high-purity monoclinic ruthenium oxide, addressing yield and activity issues in existing production methods.

KR103047850B1Active Publication Date: 2026-11-11SOGANG UNIV RES & BUSINESS DEV FOUND

Patent Information

Application Number
KR1020220080663
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2022-06-30
Publication Date
2026-11-11
Estimated Expiration
2042-06-30

AI Technical Summary

Technical Problem

Existing methods for producing monoclinic ruthenium oxide face challenges such as low yield, loss of expensive ruthenium, and decreased catalytic activity due to carbon deposition and ruthenium surface poisoning, especially under reducing conditions.

Method used

A method involving the use of solvents like formic acid, alcohol, acetonitrile, or ammonia, and injecting hydrogen or nitrogen into a hydrothermal reactor with tetragonal ruthenium oxide to achieve a hydrothermal reaction, resulting in the production of monoclinic ruthenium oxide (HxRuO2) with high purity and uniform particle size.

Benefits of technology

The method produces high-purity monoclinic ruthenium oxide with excellent dispersibility in solution and uniform particle size, minimizing ruthenium loss and maintaining high catalytic activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112022068534138-PAT00002_ABST
    Figure 112022068534138-PAT00002_ABST
Patent Text Reader

Abstract

The present invention relates to a method for manufacturing monoclinic ruthenium oxide.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a method for manufacturing monoclinic ruthenium oxide. Background Technology

[0002] Ruthenium oxide (RuO2), which exists as an ore, is a black solid with a rutile tetragonal structure. Due to its high thermal stability, resistance to acid, and conductivity, it is used in various fields such as electronic devices, electrode materials, high-efficiency capacitors, and catalysts. The structure of the ruthenium oxide is tetragonal, a crystal structure commonly found in transition metal oxides such as TiO2 or VO2. Industrially, RuO2 is obtained by high-temperature heat treatment of RuCl3 in an oxidizing atmosphere or by electroplating from a solution of RuCl3 dissolved in water. RuO2·xH2O, a hydrated ruthenium oxide, is primarily produced through electrochemical methods. It exists in a non-crystalline, amorphous state and is not very soluble in water, but it is convenient to use. For this reason, RuO2·xH2O is widely used in the manufacture of ruthenium-containing composite materials.

[0003] Meanwhile, H, a ruthenium oxide containing hydrogen x RuO2 is a black solid with a unique monoclinic structure rather than a tetragonal one; it possesses properties similar to RuO2 but is highly stable even in a reducing atmosphere containing hydrogen. On the other hand, since RuO2 readily converts to ruthenium metal as oxygen is removed in a hydrogen atmosphere, RuO2 cannot be used under reducing conditions. However, H x RuO2 has the advantage of being usable as a hydrogenation catalyst because the contained hydrogen stabilizes its structure, preventing it from being easily reduced.

[0004] The above monoclinic H xRuO2 is synthesized using tetragonal ruthenium oxide RuO2 as a starting material through the water gas shift reaction between carbon monoxide and water, and the reaction equation is represented as CO + H2O → CO2 + H2. During this process, the generated hydrogen enters the RuO2 structure, undergoing a structural transition and monoclinic H x It is known that RuO2 is formed. Since the above reaction takes place under relatively mild conditions, it has the advantage of not being easily reduced to ruthenium metal despite the generation of hydrogen. However, because high-pressure carbon monoxide is used as a reactant, ruthenium surface poisoning or Ru3(CO) 12 It has problems with formation. In addition, due to its hydrophobic characteristics, carbon deposition occurs on the surface, and consequently, H x It causes a decrease in RuO2 yield, loss of expensive ruthenium, and a decline in catalytic activity. Therefore, H x In order to utilize RuO2 as widely as RuO2 itself, it is necessary to develop a manufacturing process capable of mass production that increases yield, minimizes ruthenium loss, and maintains high catalytic activity. Prior art literature

[0005] Korean Patent Publication No. 10-2230597. The problem to be solved

[0006] The present invention aims to provide a method for manufacturing monoclinic ruthenium oxide.

[0007] However, the problems that this invention seeks to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by a person skilled in the art from the description below. means of solving the problem

[0008] One aspect of the present invention provides a method for preparing monoclinic ruthenium oxide, comprising: one or more solvents selected from formic acid, alcohol, acetonitrile, and water of ammonia; and injecting hydrogen or nitrogen into a hydrothermal reactor comprising tetragonal ruthenium oxide to hydrothermally react, thereby obtaining monoclinic ruthenium oxide represented by the following formula I:

[0009] [Chemical Formula I]

[0010] H x RuO2;

[0011] In the above chemical formula I, 0 < x ≤ 4. Effects of the invention

[0012] A method for producing monoclinic ruthenium oxide according to embodiments of the present invention comprises producing high-purity monoclinic ruthenium oxide (H2) with almost no impurities from tetragonal ruthenium oxide (RuO2). x It can generate RuO2).

[0013] Monoclinic ruthenium oxide prepared according to the embodiments of the present invention has excellent dispersibility in solution and can have a uniform particle size. Brief explanation of the drawing

[0014] Figure 1 is a graph showing X-ray powder diffraction data of monoclinic ruthenium oxide prepared according to one embodiment of the present invention. FIG. 2 is a scanning electron microscope (SEM) image of monoclinic ruthenium oxide powder prepared according to one embodiment of the present invention. Figure 3 is an X-ray photoelectron spectroscopy (XPS) graph of monoclinic ruthenium oxide powder prepared according to one embodiment of the present invention. Specific details for implementing the invention

[0015] Hereinafter, embodiments and examples of the present invention are described in detail with reference to the attached drawings so that those skilled in the art can easily implement the present invention. However, the present invention may be implemented in various different forms and is not limited to the embodiments and examples described herein. Furthermore, in order to clearly explain the present invention in the drawings, parts unrelated to the explanation have been omitted, and similar parts throughout the specification have been given similar reference numerals.

[0016] Throughout this specification, when a part is described as being "connected" to another part, this includes not only cases where they are "directly connected," but also cases where they are "electrically connected" with other elements interposed between them.

[0017] Throughout this specification, when a component is described as being located "on" another component, this includes not only cases where a component is in contact with another component, but also cases where another component exists between the two components.

[0018] Throughout this specification, when a part is described as "comprising" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.

[0019] Terms of degree used in this specification, such as “about,” “substantially,” etc., are used to mean at or near the stated value when inherent manufacturing and material tolerances are presented in the stated meaning, and are used to prevent unscrupulous infringers from unfairly exploiting the disclosure in which precise or absolute values ​​are mentioned to aid in understanding the invention.

[0020] The terms “step of” or “step of” as used throughout this specification do not mean “step for”.

[0021] Throughout this specification, the term “combination(s) of these” included in the Markush-type expression means one or more mixtures or combinations selected from the group consisting of the components described in the Markush-type expression, and means including one or more selected from the group consisting of said components.

[0022] Throughout this specification, the description of "A and / or B" means "A or B, or A and B".

[0024] Embodiments of the present invention have been described in detail below, but the present invention may not be limited thereto.

[0026] One aspect of the present invention provides a method for preparing monoclinic ruthenium oxide, comprising: one or more solvents selected from formic acid, alcohol, acetonitrile, and water of ammonia; and injecting hydrogen or nitrogen into a hydrothermal reactor comprising tetragonal ruthenium oxide to hydrothermally react, thereby obtaining monoclinic ruthenium oxide represented by the following formula I:

[0027] [Chemical Formula I]

[0028] H x RuO2;

[0029] In the above chemical formula I, 0 < x ≤ 4.

[0030] In one embodiment of the present invention, the obtained monoclinic ruthenium oxide may be obtained in powder form.

[0031] In one embodiment of the present invention, for the formula I, x (atomic ratio of hydrogen) is greater than 0 and less than or equal to 4, about 0.1 to about 3.5, about 0.1 to about 3, about 0.1 to about 2.5, about 0.1 to about 2, about 0.1 to about 1.5, about 0.1 to about 1.2, about 0.2 to about 3.5, about 0.2 to about 3, about 0.2 to about 2.5, about 0.2 to about 2, about 0.2 to about 1.5, about 0.2 to about 1.2, about 0.3 to about 3.5, about 0.3 to about 3, about 0.3 to about 2.5, about 0.3 to about 2, about 0.3 to about 1.5, about 0.3 to about 1.2, about 0.4 to about It may be 3.5, about 0.4 to about 3, about 0.4 to about 2.5, about 0.4 to about 2, about 0.4 to about 1.5, or about 0.4 to about 1.2, but is not limited thereto.

[0032] In one embodiment of the present invention, with respect to Formula I, it may be easier to produce the monoclinic ruthenium oxide as x (atomic ratio of hydrogen) approaches about 1. Specifically, if the ratio of hydrogen is about 0.6 to about 1.4, it may be easier to produce the monoclinic ruthenium oxide. Here, if x is 0 in Formula I, a structural transition to a tetragonal rutile ruthenium oxide may occur, so it is desirable to maintain the hydrogen content.

[0033] In one embodiment of the present invention, the atomic ratio of hydrogen contained in the above chemical formula I can be calculated by thermogravimetric analysis (TGA). Specifically, in the analysis using the above thermogravimetric analysis, the change in weight can be measured while raising the temperature after placing a solid sample in a platinum container. The above monoclinic ruthenium oxide (H xAll hydrogen contained in RuO2 is removed, and it is converted into tetragonal ruthenium oxide (RuO2). The amount of hydrogen can be quantitatively analyzed from the weight change with temperature.

[0034] In one embodiment of the present invention, the ruthenium oxide is such that, by X-ray powder diffraction measurement (Cu Kα line), the incident angle (2θ) is 18.38° < 2θ < 18.42°, 25.45° < 2θ < 25.51°, 26.26° < 2θ < 26.32°, 33.45° < 2θ < 33.51°, 35.28° < 2θ < 35.34°, 36.24° < 2θ < 36.30°, 37.32° < 2θ < 37.38°, 39.55° < 2θ < 39.61°, 40.61° < 2θ < 40.67°, 41.46° < 2θ < 41.52°, 49.17° < 2θ < 49.23°, Diffraction peaks may be observed at each position, such as 52.31°< 2θ <52.37°, 54.03°< 2θ <54.09°, 54.70°< 2θ <54.76°, 55.95°< 2θ <56.01°, 59.97°< 2θ <60.03°, 60.40°< 2θ <60.46°, 61.92°< 2θ <61.98°, 63.94°< 2θ <64.00°, 65.79°< 2θ <65.85°, and 69.13°< 2θ <69.19°. In one embodiment of the present invention, the ruthenium oxide may have diffraction peaks observed at each position where the incident angle (2θ), determined by X-ray powder diffraction measurement (Cu Kα line), is 18.40°, 25.48°, 26.29°, 33.48°, 35.31°, 36.27°, 37.35°, 39.58°, 40.64°, 41.49°, 49.20°, 52.34°, 54.06°, 54.73°, 55.98°, 58.00°, 60.43°, 61.95°, 63.97°, 65.82°, and 69.16°.

[0035] In one embodiment of the present invention, the ruthenium oxide may have a structure of a monoclinic space group P21 / c, C2 / m, P2 / c, C2 / c, P2 / m, or P21 / m, but is not limited thereto.

[0036] In one embodiment of the present invention, the unit cell of the monoclinic crystal structure of the monoclinic ruthenium oxide can be represented as shown in the figure below, and the lattice constants a to c and the angle between the corners can be defined as follows:

[0037]

[0038] In one embodiment of the present invention, in the monoclinic structure, 5 Å ≤ a ≤ 6 Å, 5 Å ≤ b ≤ 6 Å, and 5 Å ≤ c ≤ 6 Å, and the beta (β) angle may be about 110° to about 120°. For example, the above a to c are each independently about 5 Å to about 6 Å, about 5.1 Å to about 6 Å, about 5.2 Å to about 6 Å, about 5.3 Å to about 6 Å, about 5 Å to about 5.8 Å, about 5.1 Å to about 5.8 Å, about 5.2 Å to about 5.8 Å, about 5.3 Å to about 5.8 Å, about 5 Å to about 5.8 Å, about 5 Å to about 5.6 Å, about 5.1 Å to about 5.6 Å, about 5.2 Å to about 5.6 Å, about 5.3 Å to about 5.6 Å, about 5 Å to about 5.4 Å, about 5.1 Å to about 5.4 Å, about 5.2 Å to about 5.4 Å, about 5.3 Å to about 5.3 Å to about It may be 5.4 Å or about 5.35 Å to about 5.4 Å, and b may be about 5 Å to about 6 Å, about 5 Å to about 5.8 Å, about 5 Å to about 5.6 Å, about 5 Å to about 5.4 Å, about 5 Å to about 5.2 Å, or about 5 Å to about 5.1 Å, and the beta (β) angle may be about 110° to about 120°, about 112° to about 120°, about 114° to about 120°, about 110° to about 118°, about 112° to about 118°, about 114° to about 118°, about 110° to about 116°, about 112° to about 116°, or about 114° to about It could be 116°.

[0039] In one embodiment of the present invention, in the monoclinic structure, a=5.3533 Å, b=5.0770 Å, c=5.3532 Å, and the beta (β) angle may be 115.9074°, but is not limited thereto.

[0040] In one embodiment of the present invention, when the formic acid is used as the solvent, the purity of the tetragonal ruthenium oxide may be about 3 N (99.9 mass%) or higher. If the purity of the tetragonal ruthenium oxide is less than about 3 N, the yield of the monoclinic ruthenium oxide may decrease or ruthenium metal may be produced.

[0041] In one embodiment of the present invention, when the formic acid is used as the solvent, the weight ratio of the tetragonal ruthenium oxide to the formic acid (tetragonal ruthenium oxide:formic acid) may be greater than about 10:1 and less than about 1:20, but is not limited thereto. If the weight ratio of the tetragonal ruthenium oxide to the formic acid is about 1:20 or higher, impurities other than monoclinic ruthenium oxide may be produced, and if it is about 10:1 or lower, the rate of formation of monoclinic ruthenium oxide is very slow, and the tetragonal ruthenium oxide used as a reactant may remain unreacted.

[0042] In one embodiment of the present invention, water may be additionally included in the hydrothermal reactor, but is not limited thereto.

[0043] In one embodiment of the present invention, the water is additionally included in the hydrothermal reactor, and when the formic acid is used as the solvent, the volume ratio of the water and the formic acid (water:formic acid) may be greater than about 10:1 and less than about 0:20, but is not limited thereto. If the volume ratio of the water and the formic acid is about 0:20 or higher, impurities other than monoclinic ruthenium oxide may be produced, and if it is about 10:1 or lower, impurities other than monoclinic ruthenium oxide may be produced, and the production rate may be slow.

[0044] In one embodiment of the present invention, when a mixed solvent of formic acid and water is used by adding water to the hydrothermal reactor, the pH of the solution contained in the hydrothermal reactor may be about 1 to about 4. In one embodiment of the present invention, the pH of the solution contained in the hydrothermal reactor may be about 1 to about 4, about 1 to about 3, about 1 to about 2, about 2 to about 4, about 2 to about 3, or about 3 to about 4. If the pH of the solution is about 4 or higher, the reaction temperature may need to be increased further to produce monoclinic ruthenium oxide.

[0045] In one embodiment of the present invention, the pressure of the injected hydrogen or nitrogen may be about 0.1 MPa to about 5 MPa. In one embodiment of the present invention, the pressure of the injected hydrogen or nitrogen is about 0.1 MPa to about 0.5 MPa, about 0.1 MPa to about 0.4 MPa, about 0.1 MPa to about 0.3 MPa, about 0.1 MPa to about 0.2 MPa, about 0.2 MPa to about 0.5 MPa, about 0.2 MPa to about 0.4 MPa, about 0.2 MPa to about 0.3 MPa, about 0.3 MPa to about 0.5 MPa, about 0.3 MPa to about 0.4 MPa or about 0.4 MPa to about 0.5 MPa, about 0.1 MPa to about 5 MPa, about 0.1 MPa to about 4 MPa, about 0.1 MPa to about 3 MPa, about 0.1 MPa to about 2 MPa, about 0.1 MPa to about 1 It may be MPa, about 1 MPa to about 5 MPa, about 1 MPa to about 4 MPa, about 1 MPa to about 3 MPa, about 1 MPa to about 2 MPa, about 2 MPa to about 5 MPa, about 2 MPa to about 4 MPa, about 2 MPa to about 3 MPa, about 3 MPa to about 5 MPa, about 3 MPa to about 4 MPa, or about 4 MPa to about 5 MPa. In one embodiment of the present invention, if the pressure of hydrogen or nitrogen is less than about 0.1 MPa, the rate of formation of monoclinic ruthenium oxide may be slowed, and if it is greater than about 5 MPa, impurities of ruthenium metal or ruthenium carbonyl may be formed.

[0046] In one embodiment of the present invention, monoclinic ruthenium oxide can be produced using argon instead of hydrogen, but the production rate may be significantly reduced.

[0047] In one embodiment of the present invention, the hydrothermal reaction may be performed at about 80°C to about 150°C. In one embodiment of the present invention, the hydrothermal reaction is at about 80°C to about 150°C, about 80°C to about 140°C, about 80°C to about 130°C, about 80°C to about 120°C, about 80°C to about 110°C, about 80°C to about 100°C, about 80°C to about 90°C, about 90°C to about 150°C, about 90°C to about 140°C, about 90°C to about 130°C, about 90°C to about 120°C, about 90°C to about 110°C, about 90°C to about 100°C, about 100°C to about 150°C, about 100°C to about 140°C, about 100°C to about 130°C, about 100°C to about 120°C, about 100°C to about 100°C. It may be performed at 110°C, about 110°C to about 150°C, about 110°C to about 140°C, about 110°C to about 130°C, about 110°C to about 120°C, about 120°C to about 150°C, about 120°C to about 140°C, about 120°C to about 130°C, about 130°C to about 150°C, about 130°C to about 140°C, or about 140°C to about 150°C. In one embodiment of the present invention, in b), if the hydrothermal reaction is performed at about 60°C, the reaction may not occur well, and if it is performed at a temperature greater than about 150°C, impurities such as ruthenium metal may be generated. In one embodiment of the present invention, the hydrothermal reaction may be performed at about 100°C to about 150°C.

[0048] In one embodiment of the present invention, the hydrothermal reaction may be carried out for about 6 hours to about 12 hours. In one embodiment of the present invention, in b), the reaction may be carried out for about 6 hours to about 12 hours, about 6 hours to about 10 hours, about 6 hours to about 8 hours, about 8 hours to about 12 hours, about 8 hours to about 10 hours, or about 10 hours to about 12 hours.

[0050] The present invention will be explained in more detail below using examples, but the following examples are merely illustrative to aid in understanding the present invention, and the content of the present invention is not limited to the following examples.

[0052] [Example]

[0053] 1. Experimental Design

[0054] The following experiment involves H, a monoclinic ruthenium oxide. x This was done to investigate the effects of formic acid, distilled water, and hydrogen in the solution process for synthesizing RuO2 (0 < x ≤ 4).

[0055] 2. Examples and Comparative Examples

[0056] 1) Adjustment of the ratio of formic acid to distilled water (Examples 1 to 4)

[0057] Example 1

[0058] Ruthenium oxide (RuO2) used as a reactant was purchased from Kojundo Korea Co., Ltd. 0.1 g of the above RuO2 was placed in a 45 mL hydrothermal reactor (autoclave) along with 0.2 mL of distilled water and 0.2 mL of formic acid (reagent grade <95%), and the lid was closed. Hydrogen was flowed into the hydrothermal reactor three times to reduce the residual oxygen content in the vessel, and then the hydrothermal reactor was filled with a hydrogen pressure of 0.5 MPa. When the internal temperature of the hydrothermal reactor reached 100°C, the heating was stopped, and the reaction was carried out at that temperature for 10 hours. After the reaction, the product was vacuum dried, and the product was analyzed using X-ray diffraction.

[0059] Analysis results showed that the crystal structures of all products were monoclinic H x It was identified as RuO2, and no peak corresponding to the RuO2 used as a reactant was observed. The obtained H x The amount of RuO2 powder was 0.099 g, and based on the tetragonal RuO2 reactant, the above monoclinic H x The conversion rate of RuO2 was over 99.0%.

[0060] Entry Rutile RuO2(g) HCOOH(mL) H2O(mL) Formic acid: H2O P H2 [MPa] Temperature [°C] Time [h] Conversion Rate[%] 1 0.1 0.2 0.2 1:1 0.5 100 10 >99 2 0.1 0.2 0.4 1:2 0.5 100 10 >99 3 0.1 0.2 1.0 1:5 0.5 100 10 >99 4 0.1 0.2 - 1:0 0.5 100 10 >99

[0061] Table 1 above shows the ratio of formic acid to distilled water in Examples 1 to 4, specifically regarding monoclinic H x This shows the effect on RuO2 synthesis. Referring to Table 1 above, the presence or absence of distilled water does not significantly affect the reaction, and since the reaction proceeds even when using formic acid diluted with water, the amount of formic acid used can be reduced.

[0062] Example 2

[0063] The synthesis reaction was carried out in the same manner as in Example 1 above, except that 0.4 mL of distilled water was added and the ratio of formic acid to distilled water was adjusted to 1:2. As a result of analysis after reacting at 100°C for 10 hours under a hydrogen pressure of 0.5 MPa, the crystal structures of the products were all monoclinic H x It was RuO2.

[0064] Example 3

[0065] The synthesis reaction was carried out in the same manner as in Example 2 above, except that 1.0 mL of distilled water was added and the ratio of formic acid to distilled water was adjusted to 1:5. As a result of analysis after the reaction, the crystal structures of all products were monoclinic H x It was RuO2.

[0066] Example 4

[0067] The synthesis reaction was carried out in the same manner as in Example 2 above, except that distilled water was not added. As a result of analysis after the reaction, the crystal structures of all products were monoclinic H x It was RuO2.

[0069] 2) Control of reaction temperature (Examples 5 to 8)

[0070] Entry Rutile RuO2(g) HCOOH(mL) H2O(mL) P H2 [MPa] Temperature [°C] Time [h] Conversion Rate[%] 5 0.05 0.2 0.2 0.5 100 6 >99 6 0.05 0.2 0.2 0.5 60 6 ND 7 0.05 0.2 0.2 0.5 80 6 20.0 8 0.05 0.2 0.2 0.5 120 6 >99

[0071] Table 2 above shows that in Examples 5 to 8, the reaction temperature is monoclinic H x This shows the effect on RuO2 synthesis. Referring to Table 2 above, from a reaction temperature of 80°C or higher, monoclinic H x It can be confirmed that RuO2 is being synthesized. (ND: not detected)

[0072] Example 5

[0073] The synthesis reaction was carried out in the same manner as in Example 1 above, except that 0.05 g of RuO2 was used and the reaction was carried out for 6 hours. As a result of analysis after the reaction, the crystal structures of the products were all monoclinic Hx It was RuO2.

[0074] Example 6

[0075] The synthesis reaction was carried out in the same manner as in Example 5 above, except that 0.05 g of RuO2 was used and the reaction was performed at 60°C. As a result of analysis after the reaction, it was found that most of it was tetragonal RuO2, and monoclinic H x RuO2 was not generated.

[0076] Example 7

[0077] The synthesis reaction was carried out in the same manner as in Example 5 above, except that the reaction was performed at 80°C. Analysis after the reaction revealed that the majority was tetragonal RuO2, and monoclinic H with a conversion rate of 20%. x RuO2 was generated and mixed.

[0078] Example 8

[0079] The synthesis reaction was carried out in the same manner as in Example 5 above, except that the reaction was performed at 120°C. As a result of analysis after the reaction, the crystal structures of all products were monoclinic H x It was RuO2.

[0081] 3) Hydrogen pressure control (Examples 1, 9 and 10)

[0082] Entry Rutile RuO2(g) HCOOH(mL) H2O(mL) P H2 [MPa] P N2 [MPa] Temperature [°C] Time [h] Conversion Rate[%] 1 0.1 0.2 0.2 0.5 - 100 10 >99 9 0.1 0.2 0.2 0.1 - 100 10 95.0 10 0.1 0.2 0.2 - 0.1 100 10 85.0

[0083] Table 3 above shows that in Examples 1, 9, and 10, the hydrogen pressure is monoclinic H x This shows the effect on RuO2 synthesis. Referring to Table 3 above, it can be seen that although the reaction proceeds even without the presence of hydrogen, the presence of hydrogen added arbitrarily accelerates the reaction rate.

[0084] Example 9

[0085] The synthesis reaction was carried out in the same manner as in Example 1 above, except that the reaction was performed by applying a hydrogen pressure of 0.1 MPa. Analysis results showed tetragonal RuO2 and monoclinic Hx RuO2 was formed in a mixed manner. Based on the tetragonal RuO2 reactant, the above monoclinic H x The conversion rate of RuO2 was 95%.

[0086] Example 10

[0087] The synthesis reaction was carried out in the same manner as in Example 1 above, except that 0.1 MPa of nitrogen was added instead of hydrogen. Analysis revealed tetragonal RuO2 and monoclinic H x RuO2 was formed in a mixed manner. Based on the tetragonal RuO2 reactant, the above monoclinic H x The conversion rate of RuO2 was 85%.

[0089] 4) Control of reaction time (Examples 11 to 13)

[0090] Entry Rutile RuO2(g) HCOOH(mL) H2O(mL) P H2 [MPa] Temperature [°C] Time [h] Conversion Rate[%] 11 0.05 0.2 0.2 0.5 100 3 60.0 12 0.05 0.2 0.2 0.1 100 3 50.0 13 0.05 0.2 0.2 0.1 100 6 >99

[0091] Table 4 above shows that in Examples 11 to 13, the reaction time is monoclinic H x This shows the effect on RuO2 synthesis. Referring to Table 4 above, it can be seen that a reaction time of 6 hours is required based on 0.05 g of reactant.

[0092] Example 11

[0093] The synthesis reaction was carried out in the same manner as in Example 5 above, except that 0.05 g of RuO2 was used and the reaction was carried out for 3 hours. Analysis after the reaction revealed tetragonal RuO2 and monoclinic H x RuO2 was formed in a mixed manner. Based on the tetragonal RuO2 reactant, the above monoclinic H x The conversion rate of RuO2 was 60%.

[0094] Example 12

[0095] The synthesis reaction was carried out in the same manner as in Example 5 above, except that the reaction was carried out for 3 hours at a hydrogen pressure of 0.1 MPa. Analysis after the reaction revealed tetragonal RuO2 and monoclinic H xRuO2 was formed in a mixed manner. Based on the tetragonal RuO2 reactant, the above monoclinic H x The conversion rate of RuO2 was 50%.

[0096] Example 13

[0097] The synthesis reaction was carried out in the same manner as in Example 5 above, except that the reaction was carried out for 6 hours at a hydrogen pressure of 0.1 MPa. As a result of analysis after the reaction, the crystal structures of all products were monoclinic H x It was RuO2.

[0099] 5) Cases where a solvent other than formic acid was used (Examples 14 and 15)

[0100] Entry Rutile RuO2(g) additive P H2 [MPa] Temperature [°C] Time [h] Conversion Rate[%] 14 0.05 CH3CN 0.5 mL 0.5 100 8 >99 15 0.05 1.2 mL of NH4OH 0.5 100 8 >99

[0101] Table 5 above shows that in Examples 14 and 15, a solvent other than formic acid is monoclinic H x This indicates the effect on RuO2 synthesis. Referring to Table 5 above, when reacting with other solvents and hydrogen, monoclinic H x It was confirmed that RuO2 can be synthesized.

[0102] Example 14

[0103] 0.05 g of tetragonal RuO2 and 0.5 mL of acetonitrile were placed in a 45 mL hydrothermal reactor (autoclave) and the lid was closed. Hydrogen was flowed through the inside of the hydrothermal reactor three times to reduce the residual oxygen content in the vessel, after which the hydrothermal reactor was filled with a hydrogen pressure of 0.5 MPa. When the internal temperature of the hydrothermal reactor reached 100°C, the heating was stopped, and the reaction was carried out at this temperature for 8 hours. After drying the obtained product, it was analyzed using X-ray diffraction, and the crystal structure of the product was all monoclinic H x It was RuO2.

[0105] Example 15

[0106] The synthesis reaction was carried out in the same manner as in Example 14 above, except that 1.2 mL of NH4OH was added instead of acetonitrile. As a result of analysis after the reaction, the crystal structures of all products were monoclinic H x It was RuO2.

[0108] 6) Case where only formic acid was used (Example 16)

[0109] Entry Rutile RuO2(g) HCOOH(mL) H2O(mL) P H2 [MPa] P N2 [MPa] Temperature [°C] Time [h] Conversion Rate[%] 16 0.05 0.2 - - 0.1 100 12 >90

[0110] Table 6 above shows the monoclinic H in the presence of only formic acid in Example 16. x This indicates the effect on RuO2 synthesis. Referring to Table 6 above, even in the presence of formic acid alone, monoclinic H x It can be confirmed that RuO2 can be synthesized.

[0112] Example 16

[0113] 0.05 g of tetragonal RuO2 and 0.2 mL of formic acid were placed in a 45 mL hydrothermal reactor, and high-purity nitrogen was flowed through it three times to reduce the residual oxygen content in the vessel. Subsequently, the hydrothermal reactor was filled with nitrogen at a pressure of 0.1 MPa. When the internal temperature of the hydrothermal reactor reached 100°C, the heating was stopped, and the reaction was carried out for 12 hours. After drying the obtained product, it was analyzed using X-ray diffraction, and the results showed that the crystal structure of the product was mostly monoclinic H x It was RuO2.

[0115] Comparative Example 1: Monoclinic H synthesized via water-gas shift reaction x RuO 2

[0116] 0.1 g of square RuO2 and 0.3 mL of distilled water were placed together in a hydrothermal reactor, and the lid was closed. Carbon monoxide was injected into the hydrothermal reactor three times to reduce the oxygen content inside the vessel, and then the hydrothermal reactor was filled with carbon monoxide at a pressure of 1.0 MPa. When the internal temperature of the hydrothermal reactor reached 110°C, the heating was stopped, and the reaction was carried out for 10 hours. After the reaction, the product was washed three times with toluene, vacuum dried, and then the crystal phase was analyzed using X-ray diffraction.

[0117] Analysis results showed that the crystal structures of all products were monoclinic H x It was identified as RuO2, and no peak corresponding to RuO2 was observed. The obtained H x The amount of RuO2 powder was 0.094 g, and based on the tetragonal RuO2 reactant, the above monoclinic H x The yield of RuO2 was 94.0%. The oxidation state of ruthenium was confirmed via X-ray photoelectron spectroscopy. Monoclinic H synthesized using formic acid x Unlike RuO2, Ru of 280.0 eV 0 Through the observation of the peak, Ru3(CO) 12 It is judged that the purity is lower because it is present on the surface.

[0119] Comparative Example 2: Case where solvents such as formic acid are not used

[0120] Entry Rutile RuO2(g) HCOOH(mL) H2O(mL) P H2 [MPa] P N2 [MPa] Temperature [°C] Time [h] product 2-1 0.05 - 0.2 0.1 - 100 6 Ru metal 2-2 0.05 - 0.2 0.1 - 90 10 Ru metal 2-3 0.05 - 0.2 0.1 - 80 10 RuO2, Ru, H x RuO2

[0121] Table 7 above shows the monoclinic H in the absence of formic acid in Comparative Examples 2-1 to 2-3. x This indicates the effect on RuO2 synthesis. Referring to Table 7 above, monoclinic H₂ with only water and hydrogen without formic acid x It can be confirmed that Ru metal is always produced together when synthesizing RuO2.

[0122] Comparative Example 2-1

[0123] 0.05 g of square RuO2 and 0.2 mL of distilled water were placed in a 45 mL hydrothermal reactor, and the lid was closed. Hydrogen was flowed through the inside of the hydrothermal reactor three times to reduce the residual oxygen content in the vessel, and then the hydrothermal reactor was filled with a hydrogen pressure of 0.1 MPa. When the internal temperature of the hydrothermal reactor reached 100°C, the heating was stopped, and the reaction was carried out for 6 hours. After drying the obtained product, it was analyzed using X-ray diffraction, and the analysis results showed that the crystal structure of the product was ruthenium metal.

[0124] Comparative Example 2-2

[0125] The synthesis reaction was carried out in the same manner as Comparative Example 2-1 above, except that the reaction was carried out at 90°C for 10 hours. Analysis after the reaction revealed that the crystal structure of the product was ruthenium metal.

[0126] Comparative Example 2-3

[0127] The synthesis reaction was carried out in the same manner as in Comparative Example 2-2 above, except that the reaction was performed at 80°C. As a result of analysis after the reaction, the crystal structure of the product consisted of tetragonal RuO2, ruthenium metal, and monoclinic H x RuO2 was formed in a mixed manner. Based on the tetragonal RuO2 reactant, the above monoclinic H x The conversion rate of RuO2 was 30%.

[0128] Comparative Example 3: Cases where an acid other than formic acid was used (Comparative Examples 3-1 to 3-4)

[0129] Entry Rutile RuO2(g) additive P H2 [MPa] P N2 [MPa] Temperature [°C] Time [h] product 3-1 0.05 0.2 mL of HCl - 0.1 100 12 ND 3-2 0.05 HNO3 0.2 mL - 0.1 100 12 ND 3-3 0.05 H2SO4 0.2 mL - 0.1 100 12 ND 3-4 0.05 CH3COOH 0.2 mL - 0.1 100 12 ND

[0130] Table 8 above shows that in Comparative Examples 3-1 to 3-4, an acid other than formic acid is monoclinic H x This indicates the effect on RuO2 synthesis. Referring to Table 8 above, when an acid other than formic acid is added, monoclinic H x It can be confirmed that the RuO2 phase is not well formed.

[0131] Comparative Example 3-1

[0132] 0.05 g of tetragonal RuO2 and 0.2 mL of HCl were placed into a 45 mL hydrothermal reactor, and the lid was closed. High-purity nitrogen was flowed through the inside of the hydrothermal reactor three times to reduce the residual oxygen content in the vessel, after which the hydrothermal reactor was filled with a nitrogen pressure of 0.1 MPa. When the internal temperature of the hydrothermal reactor reached 100°C, the heating was stopped, and the reaction was carried out at that temperature for 12 hours. After drying the obtained product, it was analyzed using X-ray diffraction, and the crystal structure of the product was found to be entirely tetragonal RuO2, with monoclinic H x RuO2 was not generated.

[0133] Comparative Example 3-2

[0134] The synthesis reaction was carried out in the same manner as in Comparative Example 3-1 above, except that 0.2 mL of HNO3 was added instead of HCl. As a result of analysis after the reaction, the crystal structure of the products was all tetragonal RuO2, and monoclinic H x RuO2 was not generated.

[0135] Comparative Example 3-3

[0136] The synthesis reaction was carried out in the same manner as in Comparative Example 3-1 above, except that 0.2 mL of H2SO4 was added instead of HCl. As a result of analysis after the reaction, the crystal structure of the products was all tetragonal RuO2, and monoclinic H x RuO2 was not generated.

[0137] Comparative Example 3-4

[0138] The synthesis reaction was carried out in the same manner as in Comparative Example 3-1 above, except that 0.2 mL of CH3COOH was added instead of HCl. As a result of analysis after the reaction, the crystal structure of the products was all tetragonal RuO2, and monoclinic H x RuO2 was not generated.

[0140] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will understand that other specific forms can be easily modified without altering the technical concept or essential features of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. For example, each component described as a single unit may be implemented in a distributed manner, and components described as distributed may likewise be implemented in a combined form.

[0141] The scope of the present invention is defined by the claims set forth below rather than by the detailed description above, and all modifications or variations derived from the meaning and scope of the claims and the concept of equivalents thereof should be interpreted as being included within the scope of the present invention.

Claims

Claim 1 A method for preparing monoclinic ruthenium oxide represented by the following chemical formula I, comprising: [Chemical Formula I]H x RuO2; in the above chemical formula I, 0 < x ≤ 4. Claim 2 delete Claim 3 A method for producing monoclinic ruthenium oxide according to claim 1, wherein water is added to the hydrothermal reactor. Claim 4 A method for producing monoclinic ruthenium oxide according to claim 3, wherein the water is additionally included in the hydrothermal reactor, and when the formic acid is used as the solvent, the volume ratio of the water and the formic acid (water:formic acid) is greater than 10:1 and less than 0:

20. Claim 5 A method for producing monoclinic ruthenium oxide according to claim 1, wherein the pressure of the injected hydrogen or nitrogen is 0.1 MPa to 5 MPa. Claim 6 A method for producing monoclinic ruthenium oxide according to claim 1, wherein the pressure of the injected hydrogen or nitrogen is 0.1 MPa to 0.5 MPa. Claim 7 delete Claim 8 delete Claim 9 A method for producing monoclinic ruthenium oxide according to claim 1, wherein the hydrothermal reaction is performed for 6 to 12 hours.

Citation Information

Patent Citations

  • Hydrogen-containing ruthenium oxide, electronic device, and method for regulating and controlling physical properties of ruthenium oxide

    CN110970549A

  • Method for producing hydrogen by using hydrothermal reaction

    JP2005289742A

  • Ruthenium oxides and catalysts including the same

    KR1020220011076A

Cited By

  • Sensor and display panel and electronic device

    US12747965B2